A Trial to Investigate the Efficacy of Bendamustine in Patients With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab.

Stopped Ongoing challenges to successfully recruit the required number of subjects

Conditions

• Indolent B-cell NHL

Interventions

• DRUG: Bendamustine IV
• OTHER: Treatment of Physicians Choice

Sponsor

Mundipharma Research Limited